首页> 美国卫生研究院文献>Current Controlled Trials in Cardiovascular Medicine >Study protocol for a randomized blinded controlled trial of ketamine for acute painful crisis of sickle cell disease
【2h】

Study protocol for a randomized blinded controlled trial of ketamine for acute painful crisis of sickle cell disease

机译:氯胺酮治疗镰状细胞病急性疼痛危象的随机盲法对照试验的研究方案

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundSickle cell disease (SCD) is an inherited hematological disorder where the shape of red blood cells is altered, resulting in the destruction of red blood cells, anemia, and other complications. SCD is prevalent in the southern and eastern provinces of the Arabian peninsula. The most common complications for individuals with SCD are acute painful episodes that require several doses of intravenous opioids, making pain control for these individuals challenging. Instead of opioids, some studies have suggested that ketamine might be used for pain control in acute pain episodes of individuals with SCD. This study aims to evaluate whether the addition of ketamine to morphine can achieve better pain control, decreasing the number of repeated doses of opiates. We hypothesize that early administration of ketamine would lead to a more rapid improvement in pain score and lower opioid requirements.
机译:背景镰状细胞病(SCD)是一种遗传性血液病,其中红细胞的形状发生了改变,导致红细胞的破坏,贫血和其他并发症。 SCD在阿拉伯半岛的南部和东部省份很普遍。 SCD患者最常见的并发症是急性疼痛发作,需要多次静脉注射阿片类药物,使这些患者的疼痛控制更具挑战性。代替阿片类药物,一些研究表明氯胺酮可用于控制SCD患者的急性疼痛发作中的疼痛。这项研究旨在评估向吗啡中添加氯胺酮是否可以更好地控制疼痛,减少鸦片重复剂量的次数。我们假设氯胺酮的早期给药将导致疼痛评分更快的改善和阿片类药物的需求降低。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号